Monopar Therapeutics Q4 net loss narrows on lower R&D costs

Monopar Therapeutics

27/03/2026 17:18

Overview

US biopharmaceutical firm's Q4 net loss narrowed yr/yr

Lower R&D expenses reflect absence of one-time ALXN1840 in-licensing costs incurred in 2024

Outlook

Monopar plans to submit NDA for ALXN1840 to FDA in mid-2026

Company expects current funds to support operations through at least Dec 31, 2027

Result Drivers

LOWER R&D EXPENSES - Q4 R&D expenses fell due to absence of one-time ALXN1840 in-licensing costs from prior yr

HIGHER G&A EXPENSES - Q4 G&A expenses rose due to increased personnel costs, stock-based compensation, bonuses, and higher patent legal fees

Company press release: ID:nGNX9rJKMz

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$5.2 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Monopar Therapeutics Inc is $112.00, about 105.3% above its March 26 closing price of $54.56

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)